Swiss National Bank
LRMR icon

Swiss National Bank’s Larimar Therapeutics LRMR Stock Holding History

Swiss National Bank’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,917
Closed -$148K – 2600
2016
Q1 		$148K Buy
1,917
+400
+26% +$31.6K ﹤0.01% 2581
2015
Q4 		$114K Hold
1,517
– – ﹤0.01% 2633
2015
Q3 		$581K Buy
1,517
+250
+20% +$113K ﹤0.01% 2107
2015
Q2 		$526K Hold
1,267
– – ﹤0.01% 2214
2015
Q1 		$602K Buy
1,267
+700
+123% +$332K ﹤0.01% 2069
2014
Q4 		$210K Buy
+567
New +$146K ﹤0.01% 2490

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Swiss National Bank's LRMR Position: Q2 2016 in Review

Swiss National Bank sold out of Larimar Therapeutics (LRMR) in Q2 2016, closing a stake of 1,917 shares — an estimated $148K sold.

Swiss National Bank first reported a position in LRMR in Q4 2014 and held it in 6 quarters. The position peaked at $602K in Q1 2015. 73 funds tracked by Wall St. Rank hold LRMR as of Q2 2016.

  • Swiss National Bank reported no remaining Larimar Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Swiss National Bank sold 1,917 Larimar Therapeutics shares in Q2 2016, an estimated $148K.
  • Swiss National Bank first reported a position in Larimar Therapeutics in Q4 2014 and held it in 6 quarters.
  • Swiss National Bank's Larimar Therapeutics position peaked at $602K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2016.

Based on Swiss National Bank's 13F filing for Q2 2016, filed 3 Aug 2016.